CABG Surgery
Conditions
Keywords
CABG surgery, blood viscosity
Brief summary
After obtaining approval from the Institutional Review Board of our institution, written informed consent is obtained from patients undergoing CABG surgery are enrolled in this prospective study and randomly allocated into one of two groups: Group-C (n=15) and Group-HES (n=15). All recruited patients will be given patient identification number (PIN) for the present study of 01-30 according to their order of interview and recruitment. Investigators will prepare 15 yellow and 15 green cards, which will be inserted in 30 thick-paper envelopes. Then, all envelopes will be sealed, mixed and randomly allocated to get numbers of 01 to 30 (Envelop number). According to the color of the card, attending anesthesiologists will give crystalloid for yellow card or HES for green cards, respectively, to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture. Patient data and statistical analyses: Patient's data whole blood viscosity, PaO2, FiO2, Hemoglobin, urine amount, s-glucose will be determined from the patients' medical record after patient's discharge. All statistical analyses will be performed after the 30th patient's discharge and data acquisition
Interventions
crystalloid is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
DRUGIntravenous HES
HES is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
Sponsors
Konkuk University Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Patients undergoing CABG Surgery * Patients provided a written informed consent. * Patients with preoperative serum hemoglobin concentration \>13 g/dL (male) and \>12 g/dL (female) * Patients with PaO2/FiO2 ratio \>150
Exclusion criteria
* Patients with history of anemia, dyspnea, active infection. * Patients with endocrine disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| whole blood viscosity | with 1 hour after the completion of procedure | whole blood viscosity measured by viscometer cm-1 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| hematocrit | with 1 hour after the completion of procedure | serum hematocrit, % |
| glucose | with 1 hour after the completion of procedure | serum glucose level, g/dl |
| PaO2/FiO2 ratio | with 1 hour after the completion of procedure | PaO2/FiO2 ratio measured by arterial blood gas analysis |
| urine output | with 1 hour after the completion of procedure | hourly urine output, ml/hr |
| Maximum clot formation | with 1 hour after the completion of procedure | Maximum clot formation in rotational thromboelastometry (ROTEM) analysis, mm |
| osmolarity | with 1 hour after the completion of procedure | serum osmolarity, mOsm |
Contacts
Primary ContactTae-Yop Kim, MD, PhD
Outcome results
None listed